Table 1.

Description of study cases.

	Any prostate cancer	Palpable prostate cancer*	Advanced prostate cancer†
Cases through 12/31/2006	1408	767	385
Cases with molecular marker data	1312 (93%)	718 (94%)	362 (94%)
Age at baseline venipuncture, years
28–39	192 (15%)	71 (10%)	26 (7%)
40–43	114 (9%)	55 (8%)	25 (7%)
44–50	998 (76%)	588 (82%)	309 (85%)
51–52	8 (1%)	4 (1%)	2 (1%)
Median age at diagnosis, years (IQR)	67 (63, 71)	68 (64, 72)	68 (64, 72)
Median time from baseline to diagnosis, years (IQR)	23 (19, 25)	22 (19, 25)	22 (18, 25)
Median total PSA at diagnosis‡, ng/ml (IQR)	10.1 (6.10, 21.9)	13.0 (7.00, 34.2)	29.0 (12.8, 99.1)
Clinical T stage
T1	492 (38%)	0 (0%)	10 (3%)
T2	388 (30%)	388 (54%)	21 (6%)
T3	297 (23%)	297 (41%)	297 (82%)
T4	33 (3%)	33 (5%)	33 (9%)
Unknown	102 (8%)	0 (0%)	1 (0.3%)
Clinical N stage
N0	331 (25%)	238 (33%)	107 (30%)
N1	38 (3%)	36 (5%)	27 (7%)
Unknown	943 (72%)	444 (62%)	228 (63%)
Clinical M stage
M0	655 (50%)	445 (62%)	202 (56%)
M1	123 (9%)	112 (16%)	123 (34%)
Unknown	534 (41%)	161 (22%)	37 (10%)
WHO grade
I	278 (21%)	130 (18%)	26 (7%)
II	529 (40%)	292 (41%)	123 (34%)
III	271 (21%)	234 (33%)	178 (49%)
Unknown	234 (18%)	62 (9%)	35 (10%)
Matched controls with molecular marker data
3	1125 (86%)	601 (84%)	307 (85%)
2	166 (13%)	103 (14%)	48 (13%)
1	21 (2%)	13 (2%)	7 (2%)

IQR: interquartile range

^*Defined as clinical stage T2 or higher at diagnosis.

^†Defined as clinical stage T3 or higher, or presence of bone metastases at diagnosis.

^‡PSA within 90 days before the date of prostate cancer diagnosis; available for 1145 overall cases, 655 palpable cases, and 318 advanced cases.